Why formulation matters for emodepside treatment in dogs

Emodepside formulation may matter more than many clinicians assumed when using the drug off-label for difficult canine hookworm cases. A recent AJVR study found that giving the FDA-approved feline topical emodepside/praziquantel product orally to dogs at 1 mg/kg produced markedly higher emodepside absorption than the European canine modified-release tablet at the same dose, meaning the two formulations were not bioequivalent. In AVMA’s Veterinary Vertex discussion of the paper, the authors said the oral feline product produced about a 3-fold higher peak concentration and roughly 2.4- to 2.8-fold greater total systemic exposure than the canine tablet. The same study also found that topical administration of the feline product produced plasma concentrations 36- to 122-fold lower than oral dosing, suggesting topical use is unlikely to achieve the exposures clinicians may be seeking for multidrug-resistant hookworms. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, this is a practical reminder that formulation is part of the drug, not just the delivery route. In the US, emodepside is not approved for dogs, but it has drawn attention because prior work and clinical guidance have pointed to emodepside as a potential last-line option for suspected multidrug-resistant Ancylostoma caninum infections when standard combinations fail. Earlier reports described strong efficacy for emodepside/praziquantel against resistant hookworm isolates, and a Clinician’s Brief expert article noted successful fecal egg count reduction in client-owned dogs treated extra-label. But the new pharmacokinetic data raise the stakes around dose precision and safety, especially because matching the same mg/kg dose across products did not produce comparable exposure. That matters even more because emodepside belongs to the octadepsipeptide class, with a mechanism distinct from the major anthelmintic classes already facing resistance, and published reviews and case reports have flagged neurologic risk in dogs with MDR1 susceptibility. (pubmed.ncbi.nlm.nih.gov)

What to watch: Expect closer discussion around extra-label protocols, breed-related risk screening, and whether any canine-specific emodepside formulation or guidance emerges in the US. (pubmed.ncbi.nlm.nih.gov)